Acute myeloid leukemia ontogeny is defined by distinct somatic mutations-Reference-Cited by-同舟云学术

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Published:2015-02-26 Issue:9 Volume:125 Page:1367-1376
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lindsley R. Coleman¹,Mar Brenton G.²,Mazzola Emanuele³,Grauman Peter V.⁴,Shareef Sarah⁴,Allen Steven L.⁵,Pigneux Arnaud⁶,Wetzler Meir⁷,Stuart Robert K.⁸,Erba Harry P.⁹,Damon Lloyd E.¹⁰,Powell Bayard L.¹¹,Lindeman Neal¹²,Steensma David P.¹,Wadleigh Martha¹,DeAngelo Daniel J.¹,Neuberg Donna³,Stone Richard M.¹,Ebert Benjamin L.⁴

Affiliation:

1. Department of Medical Oncology, Division of Hematological Malignancies,

2. Department of Pediatric Oncology, and

3. Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston MA;

4. Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA;

5. Hofstra North Shore–LIJ School of Medicine, Hempstead, NY;

6. Hôpital Haut-Leveque, Centre Hospitalier Universitaire Bordeaux, Pessac, France;

7. Roswell Park Cancer Institute, Buffalo, NY;

8. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC;

9. Division of Hematology and Oncology, University of Alabama, Birmingham, Birmingham, AL;

10. Helen Diller Family Comprehensive Cancer Center, The University of California, San Francisco, CA;

11. Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC; and

12. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Abstract

Key Points The presence of a mutation in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 is highly specific for secondary AML. Secondary-type mutations define an s-AML–like disease within t-AML and elderly de novo AML that underlies clinical heterogeneity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/9/1367/1388512/1367.pdf

Reference31 articles.

1. The evolving challenge of therapy-related myeloid neoplasms.;Churpek;Best Pract Res Clin Haematol,2013

2. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.;Patel;N Engl J Med,2012

3. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.;Pfirrmann;Lancet Oncol,2012

4. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.;Cancer Genome Atlas Research Network;N Engl J Med,2013

5. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.;Kantarjian;Cancer,2006

Cited by 784 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Untangling the loops of STAG2 mutations in myelodysplastic syndrome;Leukemia & Lymphoma;2024-09-12

2. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia;Annals of Hematology;2024-09-07

3. Risk Stratification in Older Intensively Treated Patients With AML;Journal of Clinical Oncology;2024-09-04

4. A novel molecular classification based on efferocytosis-related genes for predicting clinical outcome and treatment response in acute myeloid leukemia;Inflammation Research;2024-09-02

5. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia;Leukemia Research;2024-09